STB Lifesaving Technologies has reported that $2.4m was included in the FY2010 US Department of Defense (US DoD) appropriations bill to advance the development of Fibrin Adhesive STat (FAST) dressing, a type of tissue sealant in wound care management.
STB Lifesaving said that the newly developed FAST dressing has been designed to be effective against all kinds of blood loss, including severe arterial and venous bleeding and could help save the lives of soldiers suffering from severe blood loss and closing the wounds.
According to the Combat Casualty Care Research Program, 86% of combat-related deaths occur within 30 minutes of wounding, and 50% or more are attributable to uncontrolled hemorrhaging. With better products to control bleeding, such as the STB FAST dressing, thousands of military and civilian lives could be saved.
Ron Peele, president of STB, said: “We are grateful for Senator Cardin’s continued support for STB and honored by the opportunity to serve the Department of Defense. If awarded to STB, these funds, along with funds provided by our investors, will be used to accelerate the step up to cGMP manufacturing, and the necessary planning and pre-clinical work required to file for approval by the FDA to initiate human clinical trials.”
STB Lifesaving Technologies (STB) is a privately held, pre-clinical stage, biotechnology development company located in Rockville, Maryland. STB which stands for ‘stop the bleeding’, is focused on developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. STB’s products will be indispensable to both the military and civilian medical markets.